Novartis malaria drug Coartem has expanded its approval to include babies. The combination drug, originally formulated as a tablet, has a new dose strength and formulation designed for treating newborns and young infants who develop malarial infections.
The post Novartis Drug Becomes First Malaria Therapy for Newborns and Infants appeared first on MedCity News.
